Trump administrator accused of

The Reproductive Rights Center filed a lawsuit against the Trump Administration on Friday, seeking transparency around its recent decision to review the security of the Mifepristone abortive pill.

The group filed the complaint against the Department of Health and Human Services and the Food and Medicines Administration, claiming that the Trump administration is holding information about the FDA. Annunciation that Mifepristone will revalu. CRR said that the two agencies did not respond to the requests made under the Law of Freedom of Information, a law that requires that federal agencies reviewed the records to the members of the public.

The Reproductive Rights Group is demanding the administration for information, including the FDA process to review the abortion pill and what data the agency used to decide to reassess a medication that has been widely used and safely for 25 years. CRR also demanded for information on “the influence that HHS or other parties have on the FDA review,” according to the complaint.

FDA Makary Commissioner announced In June, the agency plans to review Mifepristone, a decision that seems to be based largely on a junk science report published In April, that concluded that almost 11% of women “experience sepsis, infection, hemorrhage or other serious adverse event within 45 days after an abortion of Mifepristona.”

The timeline of events prior to Makary’s announcement “suggests political interference,” according to a CRR press release. The HHS and the FDA did not immediately respond to News themezone’s request for comments.

“The public deserves to know if the FDA is making decisions about the abortion of medicines based on discredited information or in response to political pressure,” said Rachana Desai Martin, director of programs of the United States of CRR, in a press release. “The Trump administration is pointing to a drug that has been approved by the FDA for 25 years and safely used by millions.”

Michael M. Santiago through Getty Images

The Water Science Report was financed and published by the Center for Ethics and Public Policies, a group of conservative experts and member of the Project Advisory Board 2025, the right -wing policy agenda that proposes that those named of the President in the FDA Ban Mifepristone.

The EPPC document was not reviewed by pairs and did not share its underlying data, an unusual movement that makes it impossible for other researchers to corroborate the reports of the report. Data scientists told News themezone that the report recommendations do not align with the data that says it has analyzed.

An EPPC spokesman told News themezone in April that the report was not reviewed by peers because “the extensive pro abortion bias in the pairs’ revision process” creates “there are no opportunities to publish an analysis reviewed by pairs that offer important substantive criticisms of the pill or abortion abortion.”

The EPPC report was published only a few days after Makary said he had no plans to restrict the mifepristone unless the new data suggested that it was dangerous.

Anti -abortion defenders and legislators distributed the report as proof that the mifepristone should be restricted. Senator Josh Hawley (R-MO.), An open opponent of abortion, He sent a letter For Makary urging it to “follow these new data and take all appropriate measures to restore criticisms about the use of mifepristone.” It was in response to the Hawley letter presented by the EPPC report as a fact that Makary announced his decision to review the abortive pill.

The HHS secretary, Robert F. Kennedy Jr., also told Hawley at a May Senate audience that the EPPC report was “alarming” and concluded that the mifristone should be reviewed.

“The moment of the interest of the administration in Mifepristone and its dependence on the discredited right -wing policy documents instead of the studies reviewed by long -standing peers suggest that the ideology against abortion is dictating the drug regulation process,” said Desii Martin in the CRR press release.

During an audience in the Senate last week, Kennedy told legislators that he is working with Makary to review Mifepristone. It seemed to refer to the EPPC of Sciences together, citing the same statistics of 11% used in the document findings.

“We are receiving data all the time, new data we are reviewing. And we know that during the Biden administration, they actually twisted the data to bury one of the security signals, a very high security signal, about 11%,” Kennedy said Senator James Lankford (R-Okla.). “So we will make sure that does not happen.”

Read the demand for CRR below.